Searchable abstracts of presentations at key conferences in endocrinology

ea0046p28 | (1) | UKINETS2016

Outcome of Surgical Resection after Neoadjuvant Peptide Receptor Radionuclide Therapy (PRRT) for Pancreatic Neuroendocrine Neoplasms: a case-matched analysis

Partelli Stefano , Bertani Emilio , Bartolomei Mirco , Muffatti Francesca , Grana Chiara Maria , Doglioni Claudio , Fazio Nicola , Falconi Massimo

Background: Peptide receptor radionuclide therapy (PRRT) can be an option for advanced pancreatic neuroendocrine neoplasms (PNENs) to allow patients undergo resection. Whether or not neoadjuvant PRRT increases postoperative morbidity remains unclear.Methods: Patients with initially metastatic and/or locally advanced PNEN who underwent neoadjuvant PRRT (neoadjuvant group) were compared with a group of patients who underwent upfront surgery (control group)...

ea0041ep591 | Endocrine tumours and neoplasia | ECE2016

Mtor inhibitors responsiveness associates with Akt/Mtor pathway activation in pancreatic neuroendocrine tumors

Falletta Simona , Partelli Stefano , Rubini Corrado , Nann Dominik , Doria Andrea , Marinoni Ilaria , Polenta Vanessa , Di Paquale Carmelina , Uberti Ettore Degli , Perren Aurel , Falconi Massimo , Zatelli Maria Chiara

Introduction: Medical therapy of Pancreatic neuroendocrine tumors (P-NETs) may take advantage from mammalian target of rapamycin (mTOR) inhibitors. However, so far, the extent of therapeutic response cannot be predicted.Aim: To investigate the possible predictors of sensitivity to mTOR inhibitors in P-NETs.Materials and methods: P-NET primary cultures were treated with IGF1 and/or Everolimus. Cell viability and caspase activity wer...

ea0037ep171 | Reproduction, endocrine disruptors and signalling | ECE2015

Role of TGFβ1 in pancreatic neuroendocrine tumour

Falletta Simona , Gagliano Teresa , Gentilin Erica , Di Pasquale Carmelina , Benfini Katiuscia , Polenta Vanessa , Falconi Massimo , Ambrosio Maria Rosaria , Partelli Stefano , degli Uberti Ettore , Zatelli Maria Chiara

Introduction: Neuroendocrine tumours (NETs) are heterogeneous neoplasms arising from neuroendocrine cells spread in the respiratory and gastro-entero-pancreatic epithelium. The role of transforming growth factor beta-1 (TGFβ1) in NET biology is largely unknown. TGFβ1 signalling pathway is tumour suppressive in most non-transformed epithelial cell lines. In contrast, many human carcinomas are refractory to the growth–inhibitory effects of TGFβ1.<p class=...

ea0072p1 | (1) | UKINETS2020

Post-operative NETest scores detect residual NET disease and accurately predicts tumor recurrence in R0

Modlin Irvin , Kidd Mark , Oberg Kjell , Falconi Massimo , Luigi Filosso5 Pier , Frilling Andrea , Malczewska Anna , Salem Ronald , Toumpanakis Christos , Laskaratos Faidon-Marios , Partelli Stefano , Roffinella Matteo , Arx Claudia von , Kos-Kudla Beata , Bodei Lisa , Drozdov Ignat , Kitz Alexandra

Introduction: Surgery is the only cure for neuroendocrine tumor (NET) disease. R0 resection is critical for successful tumor resection. Early detection of residual disease is key for optimal management. Both imaging and current biomarkers have intrinsic limitations and are largely ineffective up to 3 months post-surgery. NETest, a multigene blood biomarker test, identifies NETs with >90% accuracy. We hypothesized that surgery would decrease NETest levels and that elevated scor...